Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.

Autor:	Tukhvatulin AI; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Gordeychuk IV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Dolzhikova IV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Dzharullaeva AS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Krasina ME; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Bayurova EO; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Grousova DM; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Kovyrshina AV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Kondrashova AS; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Avdoshina DV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Gulyaev SA; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Gulyaeva TV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Moroz AV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Illarionova VV; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia., Zorkov ID; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Iliukhina AA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Shelkov AY; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Botikov AG; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Erokhova AS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Shcheblyakov DV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Esmagambetov IB; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Zubkova OV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Tokarskaya EA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Savina DM; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Vereveyko YR; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Ungur AS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Naroditsky BS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia., Ishmukhametov AA; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Logunov DY; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Gintsburg AL; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Emerging microbes & infections [Emerg Microbes Infect] 2022 Dec; Vol. 11 (1), pp. 2229-2247.
DOI:	10.1080/22221751.2022.2119169
Abstrakt:	Although unprecedented efforts aiming to stop the COVID-19 pandemic have been made over the past two years, SARSCoV-2 virus still continues to cause intolerable health and economical losses. Vaccines are considered the most effective way to prevent infectious diseases, which has been reaffirmed for COVID-19. However, in the context of the continuing virus spread because of insufficient vaccination coverage and emergence of new variants of concern, there is a high demand for vaccination strategy amendment. The ability to elicit protective immunity at the entry gates of infection provided by mucosal vaccination is key to block virus infection and transmission. Therefore, these mucosal vaccines are believed to be a "silver bullet" that could bring the pandemic to an end. Here, we demonstrate that the intranasally delivered Gam-COVID-Vac (Sputnik V) vaccine induced a robust (no less than 180 days) systemic and local immune response in mice. High immunogenic properties of the vaccine were verified in non-human primates (common marmosets) by marked IgG and neutralizing antibody (NtAb) production in blood serum, antigen-specific Tcell proliferation and cytokine release of peripheral blood mononuclear cells accompanied by formation of IgA antibodies in the nasal mucosa. We also demonstrate that Sputnik V vaccine can provide sterilizing immunity in K18-hACE2 transgenic mice exposed to experimental lethal SARS-CoV-2 infection protecting them against severe lung immunopathology and mortality. We believe that intranasal Sputnik V vaccine is a promising novel needle-free mucosal vaccine candidate for primary immunization as well as for revaccination and is worth further clinical investigation.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu